FMC agreed in June to sell roughly a fifth of itself at $13.30 a share to Tessenderlo Group, a Belgian industrial company. The stock purchase agreement covers 30,319,166 new shares for $403.2m, and the money is not for growth: it goes to lenders. Tessenderlo's price sits 29% above FMC's September 21 close of $10.28.

That gap is the story. FMC ended the June quarter with $4.1bn of net debt, equal to 5.2 times earnings before interest, taxes, depreciation and amortization. Room under its loan terms exists because the terms were rewritten: an April 16 credit amendment leaves the maximum leverage ratio untested for the first three quarters of 2026, sets it at 6.75x through the end of 2027, and pledges collateral. S&P Global Ratings has since cut FMC to 'BB+', below investment grade.

One molecule family, repriced

FMC sells branded insecticides, herbicides and fungicides through distributors and alliance partners, and its earnings base has for a decade rested on the diamide actives — chlorantraniliprole, sold as Rynaxypyr, and cyantraniliprole. Chlorantraniliprole's Chinese compound patent expired on August 13, 2022, after which Chinese producers scaled capacity on cost advantage and turned a premium active into a fragmented multi-supplier commodity. FMC has guided 2026 price down mid-single digits, mainly on Rynaxypyr.

The second quarter shows where the damage lands. Revenue fell 17.5% to $867.1m, volumes fell 10% on lower diamide partner orders and weak legacy-product demand, and North American sales dropped 22.4%. But sales of FMC's own differentiated post-patent diamide formulations grew more than 35% year on year. The commodity active-ingredient socket is being taken; the branded formulation business is growing. Generic economics are not a one-way street either — technical-grade chlorantraniliprole rose to $40.50 a kilogram by late March from $26.98 in January as Chinese regulators pushed compliant intermediate production.

The control that isn't falling

Corteva, FMC's closest branded competitor and now also its licensee, reported crop-protection price down 4% and volume down 2% in the June quarter, blaming Latin American competition — and still grew first-half segment operating EBITDA 9%, to $776m. The price war is industry-wide; the 10% volume drop and the 23% decline in full-year adjusted EBITDA that FMC guides to are FMC's own. Corteva's shares are up 14.1% over twelve months and its separation into two public companies targets October 1, which will hand the market a pure-play crop-protection comparable within days.

Underneath the loss line, cash turned first. Free cash flow reached $357m in the quarter, an improvement of $318m, and full-year free-cash-flow guidance was raised to $75–225m. Roughly $1bn has been assembled for debt paydown from four actions: the Tessenderlo placement, a $252m sale of the India commercial business, a $114m Newark sale-leaseback, and a $200m upfront payment from Corteva under a rimisoxafen supply and license agreement — a herbicide FMC still owns outright, not a diamide. "During the quarter, we completed several important actions that strengthened FMC's financial foundation," chairman and chief executive Pierre Brondeau said on July 29. A manufacturing restructuring approved in December targets $175m or more of annual savings by the end of 2027, at a cost of $560–635m in charges.

What the shares have done

The stock is down 71% over twelve months and 83% over two years, against a 52-week range of $9.71 to $36.18. It is not a smooth grind: it rose 13.9% on the July 30 earnings session, 13.4% on September 2 with no discoverable company news, and made a fresh 52-week low on September 18.

At 7.7 times consensus 2026 earnings of $1.33 a share and 0.79 times book, the equity screens cheap. On the whole enterprise it does not: $1.29bn of market value plus $4.1bn of net debt is about 8.3 times the midpoint of FMC's own $620–680m EBITDA guide, and the share count has 24% of dilution still to come. The business has stopped burning cash and is growing the part of the diamide franchise it can defend; the equity is a thin slice on top of a balance sheet that has to shrink before any of that reaches shareholders.

Tessenderlo's regulatory clearances were expected by the end of September or October, its finance chief said. Until that $403.2m lands, the cheapest thing about FMC is the debt the buyer is paying off.